- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Conclusions: Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. - Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Conclusions: Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. - Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Conclusions: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. - Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
Conclusions: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. - A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Conclusions: After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. - Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Conclusions: In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. - Remdesivir for the Treatment of Covid-19 — Final Report
Conclusions: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. - A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Conclusions: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit.
8 must-read COVID-19 RCTs in NEJM
